Sacubitril/Valsartan
- Generic Name
- Sacubitril/Valsartan
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
⑴用于在有慢性心力衰竭(NYHA类别II-IV)患者中减低对心力衰竭的心血管死亡及住院治疗慢性心力衰竭和射血分数降低。本品通常与其他心力衰竭治疗结合，代替一种ACE抑制药或其他血管紧张素II受体阻断药。
⑵用于治疗原发性高血压.
- Associated Conditions
- -
- Associated Therapies
- -
Early Treatment of ARNI on Myocardial Remodeling and Progress
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT04342351
- Locations
- 🇨🇳
RenJi Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, Shanghai, China
Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 300
- Registration Number
- NCT04107220
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 919
- Registration Number
- NCT04023227
- Locations
- 🇲🇽
Novartis Investigative Site, Xalapa, Mexico
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 467
- Registration Number
- NCT03988634
- Locations
- 🇺🇸
Boston Univeristy Medical Center ., Boston, Massachusetts, United States
🇺🇸Colorado Heart and Vascular ., Lakewood, Colorado, United States
🇺🇸Swedish Medical Ctr Cardiovascular Re, Seattle, Washington, United States
Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Newcastle University
- Target Recruit Count
- 168
- Registration Number
- NCT03832660
- Locations
- 🇷🇸
Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
🇮🇹Azienda Ospedaliero Universitaria Careggi Florence, Florence, Italy
🇩🇪University Hospital Regensburg, Regensburg, Germany
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 216
- Registration Number
- NCT03785405
- Locations
- 🇹🇷
Novartis Investigative Site, Konak-Izmir, Turkey
🇺🇸Mayo Clinic - Rochester, Rochester, Minnesota, United States
Prevention of Cardiac Dysfunction During Breast Cancer Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Torbjorn Omland
- Target Recruit Count
- 214
- Registration Number
- NCT03760588
- Locations
- 🇳🇴
St Olavs Hospital, Trondheim, Norway
🇳🇴University of North Norway, Tromsø, Norway
🇳🇴Akershus University Hospital, Lørenskog, Norway
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 93
- Registration Number
- NCT03552575
- Locations
- 🇬🇧
Glasgow Cardiovascular Research Centre, Glasgow, Scotland, United Kingdom
🇬🇧Glasgow Clinical Research Facility, Glasgow, Scotland, United Kingdom
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 402
- Registration Number
- NCT03387163
- Locations
- 🇺🇸
Novartis Investigative Site, New York, New York, United States
Comparing ARNI With ACE Inhibitor on Endothelial Function
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Brigham and Women's Hospital
- Registration Number
- NCT03119623
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.